Lantheus (NASDAQ:LNTH) Coverage Initiated by Analysts at Redburn Atlantic

Redburn Atlantic began coverage on shares of Lantheus (NASDAQ:LNTH) in a report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $175.00 target price on the medical equipment provider’s stock.

Several other analysts have also issued reports on LNTH. Leerink Partners boosted their target price on Lantheus from $106.00 to $127.00 and gave the company an outperform rating in a research note on Thursday, July 11th. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a buy rating on the stock in a research note on Thursday, August 1st. JMP Securities reduced their target price on shares of Lantheus from $130.00 to $125.00 and set a market outperform rating for the company in a research note on Thursday, August 1st. Finally, B. Riley upped their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a buy rating in a research note on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $126.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $105.43 on Tuesday. The firm has a 50 day moving average of $101.14 and a 200-day moving average of $80.60. The company has a market cap of $7.31 billion, a price-to-earnings ratio of 16.10 and a beta of 0.51. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the prior year, the company posted $1.40 EPS. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, equities analysts forecast that Lantheus will post 6.03 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares of the company’s stock, valued at approximately $4,990,171.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the sale, the director now owns 454,923 shares of the company’s stock, valued at $43,445,146.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now directly owns 62,557 shares of the company’s stock, valued at approximately $4,990,171.89. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,193 shares of company stock worth $3,949,202. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. International Assets Investment Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $407,000. First Horizon Advisors Inc. boosted its stake in Lantheus by 103.9% during the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock valued at $58,000 after purchasing an additional 475 shares during the last quarter. M&T Bank Corp bought a new stake in shares of Lantheus in the 4th quarter worth $320,000. Lisanti Capital Growth LLC purchased a new position in shares of Lantheus in the fourth quarter worth $1,444,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Lantheus by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider’s stock valued at $52,077,000 after purchasing an additional 7,590 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.